Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$18.86 USD
-0.54 (-2.78%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $18.62 -0.24 (-1.27%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ASMB 18.86 -0.54(-2.78%)
Will ASMB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ASMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASMB
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates
ASMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround
Other News for ASMB
Assembly Biosciences (ASMB) Showcases Promising Herpes Treatment Data
Assembly Biosciences presents Phase 1a data for ABI-5366, ABI-1179
Assembly Biosciences presents Phase 1a data for ABI-5366, ABI-1179
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & ...
Assembly announces first participant dosed in Phase 1b trial of ABI-1179